Shukra Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Shukra Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹13 of operating cash. Lower than 90% of Healthcare companies in India.
- Cash Locked Ratio: For every ₹100 of sales, ₹47 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹2 from others' credit three years earlier. More money tied up than 88% of Healthcare companies in India.
- Self-Funding Ratio: Over the last 3 years its own operating cash paid for 33% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares. Lower than 85% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹13Over the last 3 years, every ₹100 of reported profit came with ₹13 of operating cash.
Lower than 90% of Healthcare companies in India.
Self-Funding Ratio
0.3×Over the last 3 years its own operating cash paid for 33% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 85% of Healthcare companies in India.
Cash Locked Ratio
₹47For every ₹100 of sales, ₹47 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹2 from others' credit three years earlier.
More money tied up than 88% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -4% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-4% / +57%In 3 years sales changed by -4% while total assets changed by +57%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
2.2×Debt due within a year is covered 2.2 times by its yearly operating cash.
Higher than 61% of Healthcare companies in India.
Cash Cushion Ratio
+0%Cash, after subtracting all debt, equals 0% of its market value (net cash).
Higher than 59% of Healthcare companies in India.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Shukra Pharmaceuticals Limited owes ₹0.23 for every ₹1 it owns. Net profit rose 130% in the year to Mar 2026, and grew 71% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
80.2Investors pay ₹80.2 for every ₹1 of Shukra Pharmaceuticals Limited's yearly profit, higher than 86% of Healthcare companies in India.
P/B ratio
30.80The share price is 30.80 times Shukra Pharmaceuticals Limited's book value per share, higher than almost all Healthcare companies in India.
Market cap
₹2,767 CrThe total market value of all of Shukra Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 59% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹90 CrWhat Shukra Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹2.03Net worth divided by the number of shares. The share price of ₹62.53 is 30.8 times this, which is the P/B above.
Return on equity (ROE)
37.2%Shukra Pharmaceuticals Limited earned 37.2% on its shareholders' money over the last year, higher than 94% of Healthcare companies in India.
Owes vs Owns
0.23×Shukra Pharmaceuticals Limited owes ₹0.23 for every ₹1 it owns (low), lower than 77% of Healthcare companies in India.
Dividend yield
0.01%Shukra Pharmaceuticals Limited pays 0.01% of its share price as dividends a year, lower than almost all dividend-paying Healthcare companies in India.
Revenue growth
+74%Revenue rose 74% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Profit growth
+130%Net profit rose 130% in the year to Mar 2026, and grew 71% a year on average over 3 years.
Profit margin
38.9%Shukra Pharmaceuticals Limited keeps ₹39 of every ₹100 of revenue as net profit.
Cash quality
0.2×Cash from Shukra Pharmaceuticals Limited's business was 0.2× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
23.1×Shukra Pharmaceuticals Limited's operating profit covered its interest costs 23.1 times in the year to Mar 2026.
Cash vs debt
Net cashShukra Pharmaceuticals Limited held ₹1 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Shukra Pharmaceuticals Limited's P/E ratio?
Investors pay ₹80.2 for every ₹1 of Shukra Pharmaceuticals Limited's yearly profit, higher than 86% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Shukra Pharmaceuticals Limited: ₹2,767 Cr ÷ ₹90 Cr (31 Mar 2026) = 30.8.
What is Shukra Pharmaceuticals Limited's return on equity?
Shukra Pharmaceuticals Limited earned 37.2% on its shareholders' money over the last year, higher than 94% of Healthcare companies in India.
How much does Shukra Pharmaceuticals Limited owe compared with what it owns?
Shukra Pharmaceuticals Limited owes ₹0.23 for every ₹1 it owns (low), lower than 77% of Healthcare companies in India.
Does Shukra Pharmaceuticals Limited pay a dividend?
Yes. Shukra Pharmaceuticals Limited pays 0.01% of its share price as dividends a year, lower than almost all dividend-paying Healthcare companies in India.
Is Shukra Pharmaceuticals Limited's revenue growing?
Revenue rose 74% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.